[Stereotactic irradiation of liver metastases].
作者信息
Herfarth K K, Debus J, Lohr F, Bahner M L, Wannenmacher M
机构信息
Klinische Kooperationseinheit Strahlentherapeutische Onkologie, Deutsches Krebsforschungszentrum, Abt. E0500, Im Neuenheimer Feld 280, 69120 Heidelberg.
出版信息
Radiologe. 2001 Jan;41(1):64-8. doi: 10.1007/s001170050928.
PURPOSE
A number of minimal-invasive methods have been developed for the treatment of non-resectable liver metastases. A focused high dose can be delivered to a liver tumor with sparing of surrounding normal liver tissue using non-invasive stereotactic techniques.
METHODS
Sixty-six metastases were treated stereotactically in 43 patients during a phase 2 trial.
RESULTS
There were no major side effects observed. The actuarial local control was 82% after 18 months. The median actuarial survival was 24 months. However, there was a significantly improved survival in patients without additional extrahepatic tumor manifestation at the time of treatment compared to those, who were treated in palliative intention (87% vs. 24% after 18 months, p = 0.001 (log-rank).
CONCLUSION
Stereotactic single dose irradiation is a non-invasive and safe treatment option for patients with inoperable liver metastases. Phase III studies will further evaluate this new approach.
Zotero 插件